Technical Analysis for RGLS - Regulus Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -0.99% | |
| Down 3 Days in a Row | Weakness | -0.99% | |
| Down 4 Days in a Row | Weakness | -0.99% | |
| Down 5 Days in a Row | Weakness | -0.99% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 4 hours ago |
| Up 3% | about 5 hours ago |
| Up 2% | about 6 hours ago |
| Up 1% | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Oligonucleotide Hepatocellular Carcinoma RNA Regulus Therapeutics Nucleic Acids Alnylam Pharmaceuticals Atherosclerosis Hepatitis C Virus Infection Nucleotides
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Oligonucleotide Hepatocellular Carcinoma RNA Regulus Therapeutics Nucleic Acids Alnylam Pharmaceuticals Atherosclerosis Hepatitis C Virus Infection Nucleotides
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.79 |
| 52 Week Low | 1.08 |
| Average Volume | 3,987,015 |
| 200-Day Moving Average | 1.64 |
| 50-Day Moving Average | 2.40 |
| 20-Day Moving Average | 2.29 |
| 10-Day Moving Average | 2.22 |
| Average True Range | 0.23 |
| RSI (14) | 37.89 |
| ADX | 20.94 |
| +DI | 13.43 |
| -DI | 24.74 |
| Chandelier Exit (Long, 3 ATRs) | 2.21 |
| Chandelier Exit (Short, 3 ATRs) | 2.63 |
| Upper Bollinger Bands | 2.67 |
| Lower Bollinger Band | 1.91 |
| Percent B (%b) | 0.12 |
| BandWidth | 33.19 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0507 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.24 | ||||
| Resistance 3 (R3) | 2.25 | 2.18 | 2.20 | ||
| Resistance 2 (R2) | 2.18 | 2.12 | 2.18 | 2.19 | |
| Resistance 1 (R1) | 2.09 | 2.08 | 2.06 | 2.08 | 2.17 |
| Pivot Point | 2.02 | 2.02 | 2.00 | 2.02 | 2.02 |
| Support 1 (S1) | 1.93 | 1.96 | 1.90 | 1.92 | 1.83 |
| Support 2 (S2) | 1.86 | 1.92 | 1.86 | 1.81 | |
| Support 3 (S3) | 1.77 | 1.86 | 1.80 | ||
| Support 4 (S4) | 1.76 |
